{"changeSha256":"da3ea3cdfaa33d3c0bab2d8e83a3a8ef8d4a39e2f1e31262f83d23c0837f6ae9","changedAt":"2026-11-14","changedFields":[{"after":"Not an FDA-approved drug","before":"FDA compounding assessment in the cited records","field":"Status"},{"after":"A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.","before":"A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.","field":"Profile summary"},{"after":"FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.","before":"FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.","field":"Evidence note"},{"after":"fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, ctg-observation-nct07487363-2026-03-23-eb4b60623fcf, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]","before":"U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]","field":"Named organizations"},{"after":"name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tb-500/versions/4/","version":4},"id":"profile:tb-500:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule.","peptideSlugs":["tb-500"],"previousChangeEvent":{"path":"/corrections/v1/profiles/tb-500/v3.json","sha256":"b2d2db8b2b581dd5c74179e868acffed23af94ca889f8c0ab92552bbe4574afc"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tb-500/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-tb-500-briefing","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA briefing document for TB-500","url":"https://www.fda.gov/media/193349/download","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-notice-2026","name":"Federal Register · U.S. Department of Health and Human Services","sourceClass":"A","title":"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026","url":"https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-policy-2026","name":"U.S. Department of Health and Human Services","sourceClass":"A","title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications)","url":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"tb-500","type":"profile"}}
